Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUET-HCC: EB-G3B7-NK in Advanced Hepatocellular Carcinoma
NCT07500220Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EB-G3B7-NK in hepatocellular carcinoma (HCC), sponsored by Biotech Pharmaceutical. Started Mar 2026; status: recruiting.
02
Drugs
EB-G3B7-NK
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07500220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07500220.